Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

EyePoint Pharmaceuticals, Inc. Common Stock (EYPT)

Laboratory Analytical Instruments

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

480 PLEASANT STREET, SUITE B300
WATERTOWN, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/12/2008

Market Cap

414,674,385

Shares Outstanding

35,310,000

Weighted SO

48,838,843

Total Employees

N/A

Upcoming Earnings

08/07/2024

Similar Tickers

OCUP --.--%

RVPH --.--%

PLX --.--%

SLS --.--%

DRTSW --.--%

HCWB --.--%

IPHA --.--%

OBIO --.--%

CMRX --.--%

Beta

1.5990

Last Div

0.0000

Range

5.67-30.99

Chg

-0.2500

Avg Vol

850746

Mkt Cap

414674385

Exch

NASDAQ

Country

US

Phone

617 926 5000

DCF Diff

24.1376

DCF

-11.9976

Div Yield

0.0000

P/S

8.2291

EV Multiple

-3.6146

P/FV

1.8527

Div Yield %

0.0000

P/E

-4.8720

PEG

-0.1957

Payout

0.0000

Current Ratio

4.7491

Quick Ratio

4.6900

Cash Ratio

1.4616

DSO

9.9596

DIO

307.4037

Op Cycle

317.3633

DPO

1196.7982

CCC

-879.4349

Gross Margin

0.9135

Op Margin

-1.9571

Pretax Margin

-1.7213

Net Margin

-1.7229

Eff Tax Rate

-0.0220

ROA

-0.2678

ROE

-0.4324

ROCE

-0.3762

NI/EBT

1.0010

EBT/EBIT

0.8795

EBIT/Rev

-1.9571

Debt Ratio

0.0718

D/E

0.1020

LT Debt/Cap

0.0885

Total Debt/Cap

0.0926

Int Coverage

0.0000

CF/Debt

-3.8491

Equity Multi

1.4202

Rec Turnover

36.6480

Pay Turnover

0.3050

Inv Turnover

1.1874

FA Turnover

1.7276

Asset Turnover

0.1554

OCF/Share

-1.6852

FCF/Share

-1.7735

Cash/Share

5.2672

OCF/Sales

-1.7793

FCF/OCF

1.0524

CF Coverage

-3.8491

ST Coverage

-79.3469

CapEx Coverage

-19.0892

Div&CapEx Cov

-19.0892

P/BV

1.8527

P/B

1.8527

P/S

8.2291

P/E

-4.8720

P/FCF

-4.3946

P/OCF

-4.7176

P/CF

-4.7176

PEG

-0.1957

P/S

8.2291

EV Multiple

-3.6146

P/FV

1.8527

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Oct 30, 01:47 EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering Benzinga Jan 22, 09:01 Unveiling 7 Analyst Insights On EyePoint Pharmaceuticals Benzinga Dec 19, 17:05 Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December GlobeNewswire Inc. Dec 05, 20:18 EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering Benzinga Dec 05, 15:00 5 Analysts Have This to Say About EyePoint Pharmaceuticals MarketWatch Dec 04, 10:08 EyePoint Pharmaceuticals’ stock soars 212% after company announces positive data for macular degeneration treatment

Revenue Product Segmentation